Clinical trials recruiting for Non-Small Cell Lung Cancer With EGFR Mutation

Phase breakdown

Drugs and treatments being studied

Self-screener

Recruiting trials

• A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib
  NCT06668103 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 5 locations
• A Phase I Study of CFT8919 in Patients With Advanced NSCLC
  NCT06641609 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Phase Ib/II Clinical Study of GH21 Capsules Combined With Osimertinib Mesylate Tablets in Patients With NSCLC
  NCT06306456 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 6 locations
• Glutamine Plus L. Reuteri Prevents TKI Therapy-diarrhea in Patients With NSCLC
  NCT05852990 · Phase: Phase 3 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location

Related conditions

Trials recruiting for Non-Small Cell Lung Cancer With EGFR Mutation often also study these conditions. Each links to its own recruiting-trial list.

Common questions

Are these trials free to join?

Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.

How do I know if I am eligible for Non-Small Cell Lung Cancer With EGFR Mutation trials?

Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.

Is this list complete?

No. For the full list, search ClinicalTrials.gov.